Bicalutamide (Synonyms: 比卡鲁胺)

目录号: HY-14249 纯度: 99.85%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

Bicalutamide 是一种具有口服活性的非甾体雄激素受体 (AR) 拮抗剂。Bicalutamide 可用于前列腺癌的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Bicalutamide Chemical Structure

CAS No. : 90357-06-5

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥550	In-stock
50 mg	￥500	In-stock
100 mg	￥750	In-stock
200 mg	￥1100	In-stock
500 mg	￥2100	In-stock
1 g	￥3300	In-stock
5 g	现货	询价
10 g		询价
50 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Bicalutamide:

MCE 顾客使用本产品发表的 13 篇科研文献

RT-PCR

: Bicalutamide purchased from MCE. Usage Cited in: Sci Rep. 2017 Jun 8;7(1):3058. [Abstract]; CXCR7 mRNA in cells treated with 2 µM Bicalutamide (BiC) relative to untreated (UT) cells.

Bicalutamide 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer^[1].

IC₅₀ & Target

Androgen receptor^[1]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
CHO-K1	IC₅₀	200 nM Compound: 3	Displacement of [3H]mibolerone from human AR expressed in CHO-K1 cells after 2 hrs by scintillation counting Displacement of [3H]mibolerone from human AR expressed in CHO-K1 cells after 2 hrs by scintillation counting	[PMID: 20381361]
COS-1	IC₅₀	8.69 x 10^-2 μM Compound: Bic	Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay	[PMID: 25646649]
COS-7	EC₅₀	> 10 μM Compound: Bicalutamide	Agonist activity at androgen receptor expressed in Cos7 cells after 24 hrs by luciferase reporter gene assay Agonist activity at androgen receptor expressed in Cos7 cells after 24 hrs by luciferase reporter gene assay	[PMID: 22391033]
COS-7	EC₅₀	> 10 μM Compound: Bicalutamide	Agonist activity at androgen receptor T877A mutant expressed in Cos7 cells after 24 hrs by luciferase reporter gene assay Agonist activity at androgen receptor T877A mutant expressed in Cos7 cells after 24 hrs by luciferase reporter gene assay	[PMID: 22391033]
COS-7	IC₅₀	> 10 μM Compound: Bicalutamide	Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay	[PMID: 22094279]
COS-7	EC₅₀	> 10 μM Compound: Bicalutamide	Agonist activity at human androgen receptor expressed in COS7 cells assessed as luciferase activity after 24 hrs by reporter gene assay Agonist activity at human androgen receptor expressed in COS7 cells assessed as luciferase activity after 24 hrs by reporter gene assay	[PMID: 22094279]
COS-7	EC₅₀	> 10 μM Compound: Bicalutamide	Agonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as luciferase activity after 24 hrs by reporter gene assay Agonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as luciferase activity after 24 hrs by reporter gene assay	[PMID: 22094279]
COS-7	EC₅₀	0.18 μM Compound: Bicalutamide	Agonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as luciferase activity after 24 hrs by reporter gene assay Agonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as luciferase activity after 24 hrs by reporter gene assay	[PMID: 22094279]
COS-7	IC₅₀	0.33 μM Compound: Bicalutamide	Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay	[PMID: 22391033]
COS-7	IC₅₀	0.33 μM Compound: Bicalutamide	Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay	[PMID: 22094279]
COS-7	IC₅₀	0.33 μM Compound: Bicalutamide	Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay	[PMID: 23199477]
COS-7	IC₅₀	0.47 μM Compound: Bicalutamide	Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay	[PMID: 22391033]
COS-7	IC₅₀	0.47 μM Compound: Bicalutamide	Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay	[PMID: 22094279]
COS-7	IC₅₀	0.47 μM Compound: Bicalutamide	Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay	[PMID: 23199477]
CV-1	EC₅₀	> 10000 nM Compound: Bicalutamide	Agonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay Agonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay	[PMID: 18442912]
CV-1	IC₅₀	0.3 μM Compound: Casodex	Antagonist activity at human androgen receptor expressed in human CV1 cells assessed as inhibition of receptor-mediated transactivation by MMTV-luciferase reporter gene assay Antagonist activity at human androgen receptor expressed in human CV1 cells assessed as inhibition of receptor-mediated transactivation by MMTV-luciferase reporter gene assay	[PMID: 20826091]
CV-1	IC₅₀	162 nM Compound: Bicalutamide	Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay	[PMID: 18442912]
CV-1	IC₅₀	162 nM Compound: bicalutamide	Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay	[PMID: 18400499]
CWR22R	GI₅₀	3.81 μM Compound: Casodex	Growth inhibition of human CWR22Rv1 cells by MTT assay Growth inhibition of human CWR22Rv1 cells by MTT assay	[PMID: 25634130]
CWR22R	IC₅₀	4.6 μM Compound: 4	Antagonist activity at androgen receptor H874Y mutant (unknown origin) expressed in human 22Rv1 cells assessed as inhibition of DHT-induced cell growth after 3 days by WST-8 assay Antagonist activity at androgen receptor H874Y mutant (unknown origin) expressed in human 22Rv1 cells assessed as inhibition of DHT-induced cell growth after 3 days by WST-8 assay	[PMID: 24900588]
CWR22R	IC₅₀	46.25 μM Compound: Bicalutamide	Antiproliferative activity against human 22Rv1 cells after 96 hrs by Oncotest monolayer assay Antiproliferative activity against human 22Rv1 cells after 96 hrs by Oncotest monolayer assay	[PMID: 26965862]
CWR22R	IC₅₀	48.49 μM Compound: 3; Casodex; Bicalutamide	Antiproliferative activity against human 22Rv1 cells assessed as relative inhibition after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human 22Rv1 cells assessed as relative inhibition after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]
CWR22R	IC₅₀	49.577 μM Compound: 3; Casodex; Bicalutamide	Antiproliferative activity against human 22Rv1 cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human 22Rv1 cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]
CWR22R	IC₅₀	49.58 μM Compound: RS-Bicalutamide	Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay	[PMID: 27301368]
CWR22R	IC₅₀	49.6 μM Compound: 1	Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay	[PMID: 31288149]
DU-145	IC₅₀	18 μM Compound: Bicalutamide	Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
DU-145	IC₅₀	46.031 μM Compound: 3; Casodex; Bicalutamide	Antiproliferative activity against human DU145 cells assessed as relative inhibition after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human DU145 cells assessed as relative inhibition after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]
DU-145	IC₅₀	49.2 μM Compound: 1	Antiproliferative activity against human DU145 cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay Antiproliferative activity against human DU145 cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay	[PMID: 31288149]
DU-145	IC₅₀	49.2 μM Compound: RS-Bicalutamide	Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay	[PMID: 27301368]
DU-145	IC₅₀	49.2 μM Compound: 3; Casodex; Bicalutamide	Antiproliferative activity against human DU145 cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human DU145 cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]
DU-145	IC₅₀	64 μM Compound: Casodex	Cytotoxicity against human androgen-independent DU145 cells by MTT assay Cytotoxicity against human androgen-independent DU145 cells by MTT assay	[PMID: 22326399]
HEK293	IC₅₀	0.054 μM Compound: Bicalutamide	Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs	[PMID: 22391033]
HEK293	IC₅₀	0.054 μM Compound: Bicalutamide	Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs	[PMID: 22094279]
HEK293	IC₅₀	0.12 μM Compound: Bicalutamide	Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor T877A mutant expressed in HEK293 cells after 3 hrs Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor T877A mutant expressed in HEK293 cells after 3 hrs	[PMID: 22391033]
HEK293	IC₅₀	0.12 μM Compound: Bicalutamide	Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs	[PMID: 22094279]
HeLa	IC₅₀	140 nM Compound: 3	Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay	[PMID: 17804229]
HeLa	IC₅₀	140 nM Compound: 3	Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay	[PMID: 17064916]
HeLa	IC₅₀	200 nM Compound: 3	Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay	[PMID: 21050768]
LNCaP	IC₅₀	> 100 μM Compound: Casodex	Inhibition of BF3 site of androgen receptor in enzalutamide-resistant human LNCAP cells assessed as reduction in PSA level after 3 days Inhibition of BF3 site of androgen receptor in enzalutamide-resistant human LNCAP cells assessed as reduction in PSA level after 3 days	[PMID: 23301637]
LNCaP	IC₅₀	0.27 μM Compound: Bicalutamide	Inhibition of androgen receptor in human LNCAP cells after 1 day by luciferase reporter gene assay Inhibition of androgen receptor in human LNCAP cells after 1 day by luciferase reporter gene assay	[PMID: 23727044]
LNCaP	IC₅₀	0.94 μM Compound: 4	Antagonist activity at androgen receptor T877A mutant (unknown origin) expressed in human LNCAP cells assessed as inhibition of DHT-induced cell growth after 6 days by WST-8 assay Antagonist activity at androgen receptor T877A mutant (unknown origin) expressed in human LNCAP cells assessed as inhibition of DHT-induced cell growth after 6 days by WST-8 assay	[PMID: 24900588]
LNCaP	EC₅₀	1.4 μM Compound: 2	Displacement of [3H]R1881 from AR in human LNCaP cells after 2 hrs by scintillation counting analysis Displacement of [3H]R1881 from AR in human LNCaP cells after 2 hrs by scintillation counting analysis	[PMID: 23713567]
LNCaP	IC₅₀	1.71 μM Compound: Casodex	Cytotoxicity against human androgen-dependent LNCAP cells by MTT assay Cytotoxicity against human androgen-dependent LNCAP cells by MTT assay	[PMID: 22326399]
LNCaP	IC₅₀	2.38 μM Compound: BIC	Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 4 days by MTT assay in presence of DHT and E2 Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 4 days by MTT assay in presence of DHT and E2	[PMID: 26780832]
LNCaP	GI₅₀	2.61 μM Compound: Casodex	Growth inhibition of human LNCAP cells by MTT assay Growth inhibition of human LNCAP cells by MTT assay	[PMID: 25634130]
LNCaP	IC₅₀	23.79 μM Compound: Bicalutamide	Cytotoxicity against human LNCAP cells assessed as cell viability after 2 days by cell counting method Cytotoxicity against human LNCAP cells assessed as cell viability after 2 days by cell counting method	[PMID: 23727044]
LNCaP	IC₅₀	400 nM Compound: 5	Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay	[PMID: 20584610]
LNCaP	IC₅₀	45.269 μM Compound: 3; Casodex; Bicalutamide	Antiproliferative activity against human LNCAP cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human LNCAP cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]
LNCaP	IC₅₀	45.27 μM Compound: RS-Bicalutamide	Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay	[PMID: 27301368]
LNCaP	IC₅₀	45.3 μM Compound: 1	Antiproliferative activity against human LNCAP cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay Antiproliferative activity against human LNCAP cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay	[PMID: 31288149]
LNCaP	IC₅₀	47.266 μM Compound: 3; Casodex; Bicalutamide	Antiproliferative activity against human LNCAP cells assessed as relative inhibition after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human LNCAP cells assessed as relative inhibition after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]
LNCaP	IC₅₀	550 nM Compound: 3	Antagonist activity at AR in bicalutamide-resistant human LNCAP cells assessed as effect on cell proliferation after 6 days Antagonist activity at AR in bicalutamide-resistant human LNCAP cells assessed as effect on cell proliferation after 6 days	[PMID: 20381361]
LNCaP	IC₅₀	600 nM Compound: 3	Antagonist activity at AR in human bicalutamide-resistant LNCAP cells assessed as inhibition of cell proliferation after 6 days Antagonist activity at AR in human bicalutamide-resistant LNCAP cells assessed as inhibition of cell proliferation after 6 days	[PMID: 21050768]
LNCaP	IC₅₀	732.7 nM Compound: 2	Antiproliferative activity against human LNCAP cells after 3 days Antiproliferative activity against human LNCAP cells after 3 days	[PMID: 26046313]
LNCaP	IC₅₀	74 μM Compound: (R,S)Bicalutamide	Cytotoxicity against androgen-dependent human LNCAP cells after 72 hrs by SRB assay Cytotoxicity against androgen-dependent human LNCAP cells after 72 hrs by SRB assay	[PMID: 22672984]
MDA-MB-435	IC₅₀	173 nM Compound: 5	Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay	[PMID: 20584610]
PC-3	IC₅₀	> 10 μM Compound: 4	Cytotoxicity against human PC3 cells assessed as growth inhibition after 3 days by WST-8 assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 3 days by WST-8 assay	[PMID: 24900588]
PC-3	IC₅₀	60.69 μM Compound: BIC	Antiproliferative activity against AR negative human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against AR negative human PC3 cells after 48 hrs by MTT assay	[PMID: 28162857]
PC-3	IC₅₀	76.4 μM Compound: (R,S)Bicalutamide	Cytotoxicity against androgen-independent human PC3 cells after 72 hrs by SRB assay Cytotoxicity against androgen-independent human PC3 cells after 72 hrs by SRB assay	[PMID: 22672984]
PC-3	IC₅₀	77 μM Compound: Casodex	Cytotoxicity against human androgen-independent PC3 cells by MTT assay Cytotoxicity against human androgen-independent PC3 cells by MTT assay	[PMID: 22326399]
PC-3	GI₅₀	9.15 μM Compound: Casodex	Growth inhibition of human PC3 cells by MTT assay Growth inhibition of human PC3 cells by MTT assay	[PMID: 25634130]
SC-3	IC₅₀	0.67 μM Compound: 1	Antiandrogen activity against androgen receptor in androgen-dependent mouse SC3 cells assessed as inhibition of testosterone-induced cell proliferation by WST1 assay Antiandrogen activity against androgen receptor in androgen-dependent mouse SC3 cells assessed as inhibition of testosterone-induced cell proliferation by WST1 assay	[PMID: 20888766]
SC-3	IC₅₀	3 μM Compound: Bicalutamide	Antagonist activity at androgen receptor in androgen-dependent mouse SC3 cells assessed as inhibition of testosterone-induced cell growth after 3 days Antagonist activity at androgen receptor in androgen-dependent mouse SC3 cells assessed as inhibition of testosterone-induced cell growth after 3 days	[PMID: 23462715]
VCaP	IC₅₀	64.712 μM Compound: 3; Casodex; Bicalutamide	Antiproliferative activity against human VCaP cells assessed as relative inhibition after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human VCaP cells assessed as relative inhibition after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]
VCaP	IC₅₀	68.37 μM Compound: RS-Bicalutamide	Antiproliferative activity against human VCaP cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay Antiproliferative activity against human VCaP cells assessed as reduction in cell viability after 96 hrs by propidium iodide staining based fluorescence assay	[PMID: 27301368]
VCaP	IC₅₀	68.37 μM Compound: 3; Casodex; Bicalutamide	Antiproliferative activity against human VCaP cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human VCaP cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]
VCaP	IC₅₀	68.4 μM Compound: 1	Antiproliferative activity against human VCaP cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay Antiproliferative activity against human VCaP cells assessed as reduction in cell growth incubated for 96 hrs by propidium iodide based 2D monolayer assay	[PMID: 31288149]

体外研究
(In Vitro)

在全细胞结合试验 (LNCaP/AR (cs) 细胞) 中，Bicalutamide 与雄激素竞争结合 AR，IC₅₀ 为 160 nM^[1]。
Bicalutamide 以剂量依赖性方式诱导 VCaP 细胞增殖，同时部分拮抗 R1881 (合成雄激素)^[1]的作用。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Bicalutamide (10 mg/kg；ig；每天；持续 28 天) 在前列腺癌小鼠模型中表现出抗肿瘤活性^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Castrate male mice, bearing LNCaP/AR(cs) xenograft tumors^[1]
Dosage:	10 mg/kg
Administration:	Oral gavage, daily, for 28 days
Result:	Inhibited tumors growth.

Clinical Trial

分子量

430.37

Formula

C₁₈H₁₄F₄N₂O₄S

CAS 号

90357-06-5

性状

固体

颜色

White to off-white

中文名称

比卡鲁胺

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 50 mg/mL (116.18 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3236 mL	11.6179 mL	23.2358 mL
5 mM	0.4647 mL	2.3236 mL	4.6472 mL
10 mM	0.2324 mL	1.1618 mL	2.3236 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.81 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.81 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.81 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.85%

选择批次：

Data Sheet (632 KB) SDS (393 KB)

COA (287 KB) LCMS (268 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Nicola J. Clegg,1 John Wongvipat,1,2 Jim Joseph, ARN-509: a novel anti-androgen for prostate cancer treatment. Cancer Res. 2012 March 15; 72(6): 1494-1503.

Bicalutamide 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.3236 mL	11.6179 mL	23.2358 mL	58.0896 mL
	5 mM	0.4647 mL	2.3236 mL	4.6472 mL	11.6179 mL
	10 mM	0.2324 mL	1.1618 mL	2.3236 mL	5.8090 mL
	15 mM	0.1549 mL	0.7745 mL	1.5491 mL	3.8726 mL
	20 mM	0.1162 mL	0.5809 mL	1.1618 mL	2.9045 mL
	25 mM	0.0929 mL	0.4647 mL	0.9294 mL	2.3236 mL
	30 mM	0.0775 mL	0.3873 mL	0.7745 mL	1.9363 mL
	40 mM	0.0581 mL	0.2904 mL	0.5809 mL	1.4522 mL
	50 mM	0.0465 mL	0.2324 mL	0.4647 mL	1.1618 mL
	60 mM	0.0387 mL	0.1936 mL	0.3873 mL	0.9682 mL
	80 mM	0.0290 mL	0.1452 mL	0.2904 mL	0.7261 mL
	100 mM	0.0232 mL	0.1162 mL	0.2324 mL	0.5809 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Bicalutamide90357-06-5比卡鲁胺Androgen ReceptorAutophagynon-steroidalandrogenreceptorprostate cancercastration-resistantprostatecanceranti-androgenInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Bicalutamide (Synonyms: 比卡鲁胺)

Customer Review

Other Forms of Bicalutamide:

MCE 顾客使用本产品发表的 13 篇科研文献

Bicalutamide 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Bicalutamide 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Bicalutamide (Synonyms: 比卡鲁胺)

Customer Review

Other Forms of Bicalutamide:

Bicalutamide 相关抗体

MCE 顾客使用本产品发表的 13 篇科研文献

Bicalutamide 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

Bicalutamide 相关抗体:

摩尔计算器

稀释计算器

Bicalutamide 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z